Main Topics

Dabrafenib in combination with trametinib is approved by FDA for unresectable or metastatic solid tumors with BRAF V600E mutation

July 2022: Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) received accelerated approval from the Food and Drug Administration for the treatment of adult and paediatric...

All participants in a small cancer trial achieved complete remission

June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published in The...

Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma

June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval for adult patients with relapsed or...

Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications

June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration has approved the following:...

Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia

June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly diagnosed acute myeloid leukaemia...

Azacitidine is approved by FDA for newly diagnosed juvenile myelomonocytic leukemia

June 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML). The pharmacokinetics, pharmacodynamics, safety, and...

New treatment identified for low grade and serous ovarian cancer

May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the February...

Weight loss is linked to decreased risk of colon and rectal polyps

May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5...

T-cell therapy for gastric, liver and pancreatic cancer

May 2022: T-cell therapy has begun a vigorous attack on digestive system malignancies, and T-cell immunotherapy has triumphed over refractory tumours like gastric cancer, liver...

FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumors

May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA...

Patient experience of CAR T-cell therapy suffering from acute lymphoblastic leukemia

May 2022: Matthew is a 27-year-old patient with Acute Lymphoblastic Leukemia who was diagnosed in 2015. Unfortunately, the standard treatment of chemotherapy and bone marrow...

CAR T-Cell therapy for mantle cell lymphoma (MCL)

Induction therapy followed by stem cell transplantation has maintained a role in the treatment of mantle cell lymphoma (MCL), according to James Gerson, MD, who...

Need help? Our team is ready to assist you.

We wish a speedy recovery for your loved ones.

Scan the code